PE20010299A1 - DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5 - Google Patents

DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5

Info

Publication number
PE20010299A1
PE20010299A1 PE2000000672A PE0006722000A PE20010299A1 PE 20010299 A1 PE20010299 A1 PE 20010299A1 PE 2000000672 A PE2000000672 A PE 2000000672A PE 0006722000 A PE0006722000 A PE 0006722000A PE 20010299 A1 PE20010299 A1 PE 20010299A1
Authority
PE
Peru
Prior art keywords
decahydroisoquinoline
methyl
carboxyl
acid
derivatives
Prior art date
Application number
PE2000000672A
Other languages
English (en)
Spanish (es)
Inventor
David Bleakman
Amy Suzon Chappell
Paul Leslie Ornstein
Kirk Willis Johnson
Sandra Ann Filla
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20010299A1 publication Critical patent/PE20010299A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2000000672A 1999-07-06 2000-07-04 DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5 PE20010299A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14248599P 1999-07-06 1999-07-06
US15116599P 1999-08-27 1999-08-27

Publications (1)

Publication Number Publication Date
PE20010299A1 true PE20010299A1 (es) 2001-03-07

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000672A PE20010299A1 (es) 1999-07-06 2000-07-04 DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5

Country Status (28)

Country Link
US (4) US6566370B1 (enExample)
EP (1) EP1200073B1 (enExample)
JP (1) JP4619595B2 (enExample)
KR (1) KR20020024300A (enExample)
CN (1) CN1230174C (enExample)
AR (1) AR029373A1 (enExample)
AU (1) AU773304B2 (enExample)
BR (1) BR0012175A (enExample)
CA (1) CA2378613C (enExample)
CZ (1) CZ20014488A3 (enExample)
DE (1) DE60032905T2 (enExample)
DK (1) DK1200073T3 (enExample)
DZ (1) DZ3209A1 (enExample)
EA (1) EA004290B1 (enExample)
ES (1) ES2278619T3 (enExample)
HK (1) HK1047036A1 (enExample)
HR (1) HRP20020013A2 (enExample)
HU (1) HUP0202253A3 (enExample)
IL (1) IL146697A0 (enExample)
MX (1) MXPA01012726A (enExample)
MY (1) MY133503A (enExample)
NO (1) NO20016246L (enExample)
NZ (1) NZ515616A (enExample)
PE (1) PE20010299A1 (enExample)
PT (1) PT1200073E (enExample)
SK (1) SK112002A3 (enExample)
TR (1) TR200200066T2 (enExample)
WO (1) WO2001001972A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2574801A (en) * 1999-12-22 2001-07-03 Eli Lilly And Company Selective iGLUR5 receptor antagonists
CN100548299C (zh) * 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2002053139A2 (en) * 2001-01-05 2002-07-11 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
CZ20031856A3 (cs) * 2001-01-05 2003-09-17 Eli Lilly And Company Antagonisté receptorů excitačních aminokyselin
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
US6855725B2 (en) * 2001-01-05 2005-02-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2002053555A2 (en) * 2001-01-05 2002-07-11 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
PT1511741E (pt) 2002-04-26 2013-02-05 Lilly Co Eli Derivados éster de um ácido deca-hidroisoquinolino-3- carboxílico como analgésicos
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
NZ575652A (en) 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
KR20090083479A (ko) 2006-11-28 2009-08-03 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
KR20200035035A (ko) 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
WO2019171258A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Assays to detect neurodegeneration
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CA3155812A1 (en) 2019-11-08 2021-05-14 Cynthia Louise HARDEN Methods of treating depressive disorders
TW202245744A (zh) 2021-02-09 2022-12-01 加拿大商再諾製藥公司 治療失樂症之方法及用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
TR199902449T2 (xx) * 1997-04-07 2000-07-21 Eli Lilly And Company Farmakolojik etkin maddeler.
DE60002733T2 (de) 1999-07-06 2004-03-18 Eli Lilly And Co., Indianapolis Diester prodrugs von decahydroischinoline-3-carbonsäure

Also Published As

Publication number Publication date
DE60032905D1 (de) 2007-02-22
HK1047036A1 (zh) 2003-02-07
DZ3209A1 (fr) 2001-01-11
US7157582B2 (en) 2007-01-02
WO2001001972A3 (en) 2001-12-06
TR200200066T2 (tr) 2002-04-22
US6855823B2 (en) 2005-02-15
CA2378613C (en) 2007-10-02
WO2001001972A2 (en) 2001-01-11
HUP0202253A2 (hu) 2002-11-28
EA004290B1 (ru) 2004-02-26
MXPA01012726A (es) 2002-07-02
US6566370B1 (en) 2003-05-20
JP2003503449A (ja) 2003-01-28
SK112002A3 (en) 2003-05-02
NO20016246D0 (no) 2001-12-19
US6759418B2 (en) 2004-07-06
AU5873200A (en) 2001-01-22
HUP0202253A3 (en) 2003-12-29
EP1200073A2 (en) 2002-05-02
CZ20014488A3 (cs) 2003-01-15
AU773304B2 (en) 2004-05-20
US20050159445A1 (en) 2005-07-21
EP1200073B1 (en) 2007-01-10
US20030199546A1 (en) 2003-10-23
ES2278619T3 (es) 2007-08-16
US20040192722A1 (en) 2004-09-30
CN1359289A (zh) 2002-07-17
NZ515616A (en) 2004-05-28
BR0012175A (pt) 2002-03-05
PT1200073E (pt) 2007-03-30
EA200200132A1 (ru) 2002-06-27
HRP20020013A2 (en) 2003-08-31
IL146697A0 (en) 2002-07-25
NO20016246L (no) 2002-03-04
CA2378613A1 (en) 2001-01-11
CN1230174C (zh) 2005-12-07
MY133503A (en) 2007-11-30
JP4619595B2 (ja) 2011-01-26
AR029373A1 (es) 2003-06-25
KR20020024300A (ko) 2002-03-29
DE60032905T2 (de) 2007-10-18
DK1200073T3 (da) 2007-05-07

Similar Documents

Publication Publication Date Title
IS6362A (is) Úrea (eða þvagefnis) efnasambönd sem hafa múskarín viðtaka mótlyfs virkni
BR0114045A (pt) Poliarilcarboxamidas úteis como agentes redutores de lipìdeos
PE1998A1 (es) DERIVADOS DE BENZO [g] QUINOLINA
EA200100755A1 (ru) 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
EA199800604A1 (ru) Производные 1-(1,2-дизамещенный пиперидинил)-4-замещенного пиперидинина как антагонисты рецепторов тахикинина
DK1177176T3 (da) Triarylsyrederivater som PPAR-receptorligander
DK0765314T3 (da) Benzoheterocykliske derivater, der kan anvendes som vasopressin- eller oxytocinmodulatorer
DE69006131D1 (de) Substituierte Chinazolinone als Angiotensin II-Antagonisten.
AR022230A1 (es) Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
TR200102839T2 (tr) LH agonistleri olarak faydalı bisiklik heteroaromatik bileşikler.
PE20011029A1 (es) Compuestos de dihidropirimidina heterociclicos como inhibidores del canal de potasio
EA200300391A1 (ru) Имидазольные соединения, арил- или гетероарилконденсированные, в качестве противовоспалительных и анальгетических средств
PE20011314A1 (es) DERIVADOS DE N-(4-CARBAMIMIDOIL-FENIL)-GLICINA COMO INHIBIDORES DE LA FORMACION DE FACTORES DE COAGULACION Xa IXa Y TROMBINA
SE9904508D0 (sv) New compounds
TR200102489T2 (tr) 3-Fenilpiridin Türevleri ve bunların NK-1 alıcı antagonistler olarak kullanılması
EA200401167A1 (ru) Производные тропана в качестве модуляторов ccr5
ATE340795T1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
ES2168383T3 (es) Derivados de 1,2,3,4-tetrahidroquinoxalindiona y su utilizacion como antagonistas del glutamato receptor.
EP0915094A4 (en) MORPHINANE DERIVATIVES AND MEDICAL USE THEREOF
EA200000804A1 (ru) Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина
ZA200106514B (en) Heterocyclic compounds intermediates thereof and elastase inhibitors.
MA27501A1 (fr) Derives d'imidazoquinoline en tant que ligands recepteurs de l'adenosine a3
AR018877A1 (es) Un procedimiento para la preparacion de derivados de morfolina
ATE416174T1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed